$430 K

RSPI Mkt cap, 21-May-2020
RespireRx Pharmaceuticals Net income (Q1, 2020)-946.7 K
RespireRx Pharmaceuticals EBIT (Q1, 2020)-520.6 K
RespireRx Pharmaceuticals Cash, 31-Mar-202081
RespireRx Pharmaceuticals EV1.5 M

RespireRx Pharmaceuticals Income Statement

Annual

USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

3.1m48.3k61.7k86.9k

R&D expense

2.2m826.7k206.9k591.8k1.7m3.2m1.7m688.3k599.3k

General and administrative expense

3.2m1.9m933.0k3.8m3.6m5.3m2.5m1.5m1.1m

Operating expense total

5.4m2.8m1.1m4.4m5.3m8.5m4.2m2.2m1.7m

EBIT

(2.3m)(7.3m)(1.1m)(4.4m)(5.2m)(8.5m)(4.2m)(2.2m)(1.7m)

EBIT margin, %

(73%)(15177%)(7060%)(6028%)

Interest expense

6.9k9.0

Interest income

92.08.0

Net Income

(2.3m)(7.6m)(1.2m)(2.7m)(6.0m)(9.2m)(4.3m)(2.6m)(2.1m)

RespireRx Pharmaceuticals Balance Sheet

Annual

USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

1.6m152.2k14.4k162.8k53.2k92.0k84.9k33.3k16.7k

Accounts Receivable

116.0m

Prepaid Expenses

85.6k17.0k2.4k29.1k42.9k38.9k28.6k

Inventories

4.6m

Current Assets

1.7m169.2k51.9k320.7k85.8k195.7k176.7k121.1k45.3k

PP&E

66.9k16.7k12.1k

Total Assets

1.8m198.7k51.9k400.3k145.8k233.8k194.8k124.2k45.3k

Accounts Payable

472.8k1.5m1.8m1.8m1.4m2.6m2.9m3.3m3.8m

Short-term debt

99.7k8.9k1.3m

Current Liabilities

1.1m3.2m4.2m2.6m3.0m5.7m4.6m5.9m7.5m

Total Debt

99.7k8.9k1.3m

Total Liabilities

1.1m

Common Stock

85.6k144.0k144.0k232.1k489.8k3.1k3.9k4.2k

Preferred Stock

21.7k21.7k21.7k21.7k

Additional Paid-in Capital

121.3m125.2m125.2m139.0m144.6m152.0m157.4m158.6m159.0m

Retained Earnings

(120.8m)(128.3m)(129.5m)(142.3m)(148.3m)(157.5m)(161.8m)(164.4m)(166.5m)

Total Equity

675.9k(3.0m)(4.2m)(2.2m)(2.9m)(5.5m)(4.4m)(5.7m)(7.4m)

Financial Leverage

2.7 x-0.1 x0 x-0.2 x-0.1 x0 x0 x0 x0 x

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

Cash

1.4m438.4k778.4k532.9k224.3k7.6k25.6k10.0k311.9k172.7k32.9k154.2k53.2k404.5k6.1k347.3k39.6k220.9k30.8k52.2k266.0874.080.7k5.5k6.094.081.0

Prepaid Expenses

61.4k47.6k59.9k47.4k1.5k98.1k15.1k23.8k58.4k43.5k76.5k69.7k68.6k108.7k83.5k60.3k100.7k82.6k67.1k90.4k101.2k57.7k100.0k

Current Assets

1.5m536.4k886.7k600.9k234.9k105.7k54.0k33.3k365.2k239.7k86.1k318.6k154.9k448.0k82.6k528.7k157.0k378.6k163.3k161.5k149.8k132.4k196.7k144.8k150.2k106.7k100.1k

PP&E

198.2k100.5k56.0k48.4k45.6k1.9k1.7k13.4k17.3k15.6k13.9k10.4k8.6k6.9k3.5k1.9k307.0

Total Assets

1.8m678.3k951.6k678.8k3.7m135.3k54.0k33.3k441.2k311.8k166.2k395.1k226.0k513.6k137.2k577.8k200.7k411.3k190.7k183.6k164.2k143.0k203.6k144.8k150.2k106.7k100.1k

Accounts Payable

568.3k607.9k521.1k811.9k1.3m1.7m1.8m1.8m1.9m1.5m1.6m2.2m1.5m1.4m1.8m1.9m2.3m2.7m2.8m3.0m3.0m3.1m3.3m3.4m3.6m3.7m4.1m

Short-term debt

271.9k77.040.2k77.5k79.9k82.3k64.0k49.3k30.7k1.1m

Current Liabilities

1.2m1.3m1.2m1.8m2.8m4.0m4.1m4.1m2.9m2.5m2.3m3.0m2.8m2.6m3.9m4.3m5.0m6.3m6.5m6.9m5.1m5.2m5.6m6.4m6.8m7.1m7.6m

Total Debt

271.9k77.040.2k77.5k79.9k82.3k64.0k49.3k30.7k1.1m

Total Liabilities

1.2m1.3m3.0m

Common Stock

78.9k78.9k85.6k85.6k144.0k144.0k144.0k144.0k201.0k201.0k210.4k240.8k413.5k477.2k498.6k656.2k2.0k2.3k2.3k2.6k3.1k3.4k3.6k3.9k3.9k3.9k33.7k

Preferred Stock

21.7k21.7k21.7k21.7k21.7k21.7k21.7k21.7k21.7k21.7k21.7k21.7k

Additional Paid-in Capital

120.9m120.9m121.4m121.5m125.2m125.2m125.2m125.2m128.7m137.6m138.2m139.3m141.0m143.7m146.4m149.3m151.2m153.0m154.2m154.4m157.5m158.1m158.3m158.7m158.8m158.8m159.9m

Retained Earnings

(120.4m)(121.6m)(121.7m)(122.7m)(124.5m)(129.2m)(129.4m)(129.5m)(132.1m)(140.9m)(141.6m)(143.0m)(144.3m)(146.6m)(151.0m)(153.7m)(156.1m)(159.0m)(160.6m)(161.2m)(162.5m)(163.2m)(163.7m)(164.9m)(165.4m)(165.9m)(167.5m)

Total Equity

533.9k(645.8k)(241.1k)(1.1m)881.3k(3.8m)(4.0m)(4.1m)(2.5m)(2.2m)(2.1m)(2.6m)(2.6m)(2.1m)(3.8m)(3.7m)(4.8m)(5.9m)(6.3m)(6.8m)(5.0m)(5.1m)(5.4m)(6.2m)(6.6m)(7.0m)(7.5m)

Debt to Equity Ratio

0 x

Debt to Assets Ratio

0 x

Financial Leverage

3.3 x-1.1 x-3.9 x-0.6 x4.2 x0 x0 x0 x-0.2 x-0.1 x-0.1 x-0.2 x-0.1 x-0.2 x0 x-0.2 x0 x-0.1 x0 x0 x0 x0 x0 x0 x0 x0 x0 x

RespireRx Pharmaceuticals Cash Flow

Annual

USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(2.3m)(7.6m)(1.2m)(2.7m)(6.0m)(9.2m)(4.3m)(2.6m)(2.1m)

Depreciation and Amortization

107.0k26.4k1.7k7.1k7.0k5.2k

Accounts Receivable

(48.0k)48.0k

Accounts Payable

84.2k871.9k321.8k452.1k490.4k1.2m476.4k703.7k524.3k

Cash From Operating Activities

(1.9m)(1.9m)(182.4k)(885.9k)(1.3m)(1.3m)(697.0k)(427.4k)(487.7k)

Purchases of PP&E

(5.3k)

Cash From Investing Activities

2.0m24.7k(18.4k)(2.5k)

Cash From Financing Activities

477.8k378.4k44.6k1.1m1.2m1.4m689.9k375.8k471.2k

Net Change in Cash

573.4k(1.5m)(137.8k)148.4k(109.6k)38.8k(7.1k)(51.6k)(16.6k)

Interest Paid

102.06.9k1.1k2.6k3.3k5.1k

RespireRx Pharmaceuticals Ratios

USDY, 2020

EV/EBIT

-2.9 x

EV/CFO

-85.9 x

RespireRx Pharmaceuticals Operating Metrics

FY, 2016

Phase I Trials Products

1

Phase II Trials Products

4

Preclinical Phase Products

1